Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study.

Hargrave DR, Bouffet E, Tabori U, Broniscer A, Cohen KJ, Hansford JR, Geoerger B, Hingorani P, Dunkel IJ, Russo MW, Tseng L, Dasgupta K, Gasal E, Whitlock JA, Kieran MW.

Clin Cancer Res. 2019 Dec 6. doi: 10.1158/1078-0432.CCR-19-2177. [Epub ahead of print]

PMID:
31811016
2.

Defining optimal target volumes of conformal radiation therapy for diffuse intrinsic pontine glioma.

Tinkle CL, Simone B, Chiang JCH, Li X, Campbell K, Han Y, Li Y, Hover LD, Molitoris JK, Becksfort J, Lucas JT Jr, Patay Z, Baker SJ, Broniscer A, Merchant TE.

Int J Radiat Oncol Biol Phys. 2019 Nov 27. pii: S0360-3016(19)34056-8. doi: 10.1016/j.ijrobp.2019.11.020. [Epub ahead of print]

PMID:
31785339
3.

Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumors.

Panetta JC, Roberts JK, Huang J, Lin T, Daryani VM, Harstead KE, Patel YT, Onar-Thomas A, Campagne O, Ward DA, Broniscer A, Robinson G, Gajjar A, Stewart CF.

Br J Clin Pharmacol. 2019 Oct 28. doi: 10.1111/bcp.14160. [Epub ahead of print]

PMID:
31657864
4.

A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation-Positive Solid Tumors.

Kieran MW, Geoerger B, Dunkel IJ, Broniscer A, Hargrave D, Hingorani P, Aerts I, Bertozzi AI, Cohen KJ, Hummel TR, Shen V, Bouffet E, Pratilas CA, Pearson ADJ, Tseng L, Nebot N, Green S, Russo MW, Whitlock JA.

Clin Cancer Res. 2019 Sep 10. doi: 10.1158/1078-0432.CCR-17-3572. [Epub ahead of print]

PMID:
31506385
5.

Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors.

Reddick SJ, Campagne O, Huang J, Onar-Thomas A, Broniscer A, Gajjar A, Stewart CF.

Cancer Chemother Pharmacol. 2019 Oct;84(4):829-838. doi: 10.1007/s00280-019-03921-3. Epub 2019 Aug 7.

PMID:
31392390
6.

Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas.

Koncar RF, Dey BR, Stanton AJ, Agrawal N, Wassell ML, McCarl LH, Locke AL, Sanders L, Morozova-Vaske O, Myers MI, Hamilton RL, Carcaboso AM, Kohanbash G, Hu B, Amankulor NM, Felker J, Kambhampati M, Nazarian J, Becher OJ, James CD, Hashizume R, Broniscer A, Pollack IF, Agnihotri S.

Cancer Res. 2019 Aug 15;79(16):4026-4041. doi: 10.1158/0008-5472.CAN-18-3521. Epub 2019 Jun 14.

PMID:
31201162
7.

Correction to: H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo.

Silveira AB, Kasper LH, Fan Y, Jin H, Wu G, Shaw TI, Zhu X, Larson JD, Easton J, Shao Y, Yergeau DA, Rosencrance C, Boggs K, Rusch MC, Ding L, Zhang J, Finkelstein D, Noyes RM, Russell BL, Xu B, Broniscer A, Wetmore C, Pounds SB, Ellison DW, Zhang J, Baker SJ.

Acta Neuropathol. 2019 Jun;137(6):1021. doi: 10.1007/s00401-019-02006-y. Epub 2019 Apr 11.

PMID:
30976974
8.

Is Schimmelpenning Syndrome Associated with Intracranial Tumors? A Case Report.

Chiang MC, McDowell MM, Weaver K, Broniscer A, Greene S.

Pediatr Neurosurg. 2019;54(3):201-206. doi: 10.1159/000497149. Epub 2019 Mar 15.

PMID:
30879010
9.

Childhood brain tumors: current management, biological insights, and future directions.

Pollack IF, Agnihotri S, Broniscer A.

J Neurosurg Pediatr. 2019 Mar 1;23(3):261-273. doi: 10.3171/2018.10.PEDS18377. Review.

10.

H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo.

Silveira AB, Kasper LH, Fan Y, Jin H, Wu G, Shaw TI, Zhu X, Larson JD, Easton J, Shao Y, Yergeau DA, Rosencrance C, Boggs K, Rusch MC, Ding L, Zhang J, Finkelstein D, Noyes RM, Russell BL, Xu B, Broniscer A, Wetmore C, Pounds SB, Ellison DW, Zhang J, Baker SJ.

Acta Neuropathol. 2019 Apr;137(4):637-655. doi: 10.1007/s00401-019-01975-4. Epub 2019 Feb 15. Erratum in: Acta Neuropathol. 2019 Jun;137(6):1021.

PMID:
30770999
11.

Evaluation of 11C-Methionine PET and Anatomic MRI Associations in Diffuse Intrinsic Pontine Glioma.

Tinkle CL, Duncan EC, Doubrovin M, Han Y, Li Y, Kim H, Broniscer A, Snyder SE, Merchant TE, Shulkin BL.

J Nucl Med. 2019 Mar;60(3):312-319. doi: 10.2967/jnumed.118.212514. Epub 2018 Aug 2.

12.

Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries.

Hoffman LM, Veldhuijzen van Zanten SEM, Colditz N, Baugh J, Chaney B, Hoffmann M, Lane A, Fuller C, Miles L, Hawkins C, Bartels U, Bouffet E, Goldman S, Leary S, Foreman NK, Packer R, Warren KE, Broniscer A, Kieran MW, Minturn J, Comito M, Broxson E, Shih CS, Khatua S, Chintagumpala M, Carret AS, Escorza NY, Hassall T, Ziegler DS, Gottardo N, Dholaria H, Doughman R, Benesch M, Drissi R, Nazarian J, Jabado N, Boddaert N, Varlet P, Giraud G, Castel D, Puget S, Jones C, Hulleman E, Modena P, Giagnacovo M, Antonelli M, Pietsch T, Gielen GH, Jones DTW, Sturm D, Pfister SM, Gerber NU, Grotzer MA, Pfaff E, von Bueren AO, Hargrave D, Solanki GA, Jadrijevic Cvrlje F, Kaspers GJL, Vandertop WP, Grill J, Bailey S, Biassoni V, Massimino M, Calmon R, Sanchez E, Bison B, Warmuth-Metz M, Leach J, Jones B, van Vuurden DG, Kramm CM, Fouladi M.

J Clin Oncol. 2018 Jul 1;36(19):1963-1972. doi: 10.1200/JCO.2017.75.9308. Epub 2018 May 10.

13.

Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma.

Broniscer A, Jia S, Mandrell B, Hamideh D, Huang J, Onar-Thomas A, Gajjar A, Raimondi SC, Tatevossian RG, Stewart CF.

Pediatr Blood Cancer. 2018 Jul;65(7):e27035. doi: 10.1002/pbc.27035. Epub 2018 Mar 7.

14.

Malignant progression of a peripheral nerve sheath tumor in the setting of rhabdoid tumor predisposition syndrome.

Upadhyaya SA, McGee RB, Wilky BA, Broniscer A.

Pediatr Blood Cancer. 2018 Jul;65(7):e27030. doi: 10.1002/pbc.27030. Epub 2018 Mar 7.

15.

Malignant rhabdoid tumors originating within and outside the central nervous system are clinically and molecularly heterogeneous.

Pinto EM, Hamideh D, Bahrami A, Orr BA, Lin T, Pounds S, Zambetti GP, Pappo AS, Gajjar A, Agnihotri S, Broniscer A.

Acta Neuropathol. 2018 Aug;136(2):315-326. doi: 10.1007/s00401-018-1814-2. Epub 2018 Feb 10.

16.

Treatment-Related Noncontiguous Radiologic Changes in Children With Diffuse Intrinsic Pontine Glioma Treated With Expanded Irradiation Fields and Antiangiogenic Therapy.

Patay Z, Merchant TE, Nguyen R, Pierson CR, Onar-Thomas A, Broniscer A.

Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1295-1305. doi: 10.1016/j.ijrobp.2017.08.021. Epub 2017 Aug 24.

17.

A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas.

Kilburn LB, Kocak M, Baxter P, Poussaint TY, Paulino AC, McIntyre C, Lemenuel-Diot A, Lopez-Diaz C, Kun L, Chintagumpala M, Su JM, Broniscer A, Baker JN, Hwang EI, Fouladi M, Boyett JM, Blaney SM.

Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26832. Epub 2017 Nov 1.

18.

Prognostic Relevance of Treatment Failure Patterns in Pediatric High-Grade Glioma: Is There a Role for a Revised Failure Classification System?

Lucas JT Jr, Cooper DA, Hwang S, Tinkle C, Li X, Li Y, Orr B, Merchant TE, Broniscer A.

Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):450-458. doi: 10.1016/j.ijrobp.2017.04.039. Epub 2017 May 4.

PMID:
28871996
19.

Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study.

Cooney T, Lane A, Bartels U, Bouffet E, Goldman S, Leary SES, Foreman NK, Packer RJ, Broniscer A, Minturn JE, Shih CS, Chintagumpala M, Hassall T, Gottardo NG, Dholaria H, Hoffman L, Chaney B, Baugh J, Doughman R, Leach JL, Jones BV, Fouladi M, Warren KE, Monje M.

Neuro Oncol. 2017 Sep 1;19(9):1279-1280. doi: 10.1093/neuonc/nox107. No abstract available.

20.

Mortality in children with low-grade glioma or glioneuronal tumors: A single-institution study.

Upadhyaya SA, Ghazwani Y, Wu S, Broniscer A, Boop FA, Gajjar A, Qaddoumi I.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26717. Epub 2017 Jul 14.

21.

Posttreatment DSC-MRI is Predictive of Early Treatment Failure in Children with Supratentorial High-Grade Glioma Treated with Erlotinib.

Lucas JT Jr, Knapp BJ, Uh J, Hua CH, Merchant TE, Hwang SN, Patay Z, Broniscer A.

Clin Neuroradiol. 2018 Sep;28(3):393-400. doi: 10.1007/s00062-017-0580-1. Epub 2017 Apr 5.

22.

Rapid and fulminant leptomeningeal spread following radiotherapy in diffuse intrinsic pontine glioma.

Tinkle CL, Orr BA, Lucas JT Jr, Klimo P, Patay Z, Baker SJ, Broniscer A, Qaddoumi I.

Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26416. Epub 2017 Jan 13.

23.

11C-Methionine positron emission tomography delineates non-contrast enhancing tumor regions at high risk for recurrence in pediatric high-grade glioma.

Lucas JT Jr, Serrano N, Kim H, Li X, Snyder SE, Hwang S, Li Y, Hua CH, Broniscer A, Merchant TE, Shulkin BL.

J Neurooncol. 2017 Mar;132(1):163-170. doi: 10.1007/s11060-016-2354-z. Epub 2017 Jan 11.

PMID:
28078638
24.

Bithalamic gliomas may be molecularly distinct from their unilateral high-grade counterparts.

Broniscer A, Hwang SN, Chamdine O, Lin T, Pounds S, Onar-Thomas A, Chi L, Shurtleff S, Allen S, Gajjar A, Northcott P, Orr BA.

Brain Pathol. 2018 Jan;28(1):112-120. doi: 10.1111/bpa.12484. Epub 2017 Mar 12.

25.

Clinical Characteristics and Long-Term Outcomes of Movement Disorders in Childhood Thalamic Tumors.

Sadighi ZS, Zabrowski J, Boop FA, Broniscer A, Gajjar A, Khan RB.

Pediatr Neurol. 2016 Dec;65:71-77. doi: 10.1016/j.pediatrneurol.2016.08.012. Epub 2016 Aug 22.

PMID:
27773422
26.

Discrepant longitudinal volumetric and metabolic evolution of diffuse intrinsic Pontine gliomas during treatment: implications for current response assessment strategies.

Löbel U, Hwang S, Edwards A, Li Y, Li X, Broniscer A, Patay Z.

Neuroradiology. 2016 Oct;58(10):1027-1034. Epub 2016 Jul 20.

27.

Children with minimal chance for cure: parent proxy of the child's health-related quality of life and the effect on parental physical and mental health during treatment.

Mandrell BN, Baker J, Levine D, Gattuso J, West N, Sykes A, Gajjar A, Broniscer A.

J Neurooncol. 2016 Sep;129(2):373-81. doi: 10.1007/s11060-016-2187-9. Epub 2016 Jun 25.

28.

Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant.

Roberts JK, Birg AV, Lin T, Daryani VM, Panetta JC, Broniscer A, Robinson GW, Gajjar AJ, Stewart CF.

Drug Metab Dispos. 2016 Jul;44(7):1116-22. doi: 10.1124/dmd.115.068676. Epub 2016 Apr 6.

29.

Gliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas.

Broniscer A, Chamdine O, Hwang S, Lin T, Pounds S, Onar-Thomas A, Shurtleff S, Allen S, Gajjar A, Northcott P, Orr BA.

Acta Neuropathol. 2016 Feb;131(2):299-307. doi: 10.1007/s00401-015-1532-y. Epub 2016 Jan 7.

30.

Malignant brainstem tumors in children, excluding diffuse intrinsic pontine gliomas.

Klimo P Jr, Nesvick CL, Broniscer A, Orr BA, Choudhri AF.

J Neurosurg Pediatr. 2016 Jan;17(1):57-65. doi: 10.3171/2015.6.PEDS15166. Epub 2015 Oct 16.

PMID:
26474099
31.

Metastatic Low-Grade Gliomas in Children: 20 Years' Experience at St. Jude Children's Research Hospital.

Chamdine O, Broniscer A, Wu S, Gajjar A, Qaddoumi I.

Pediatr Blood Cancer. 2016 Jan;63(1):62-70. doi: 10.1002/pbc.25731. Epub 2015 Aug 27.

32.

Pulmonary Function After Treatment for Embryonal Brain Tumors on SJMB03 That Included Craniospinal Irradiation.

Green DM, Merchant TE, Billups CA, Stokes DC, Broniscer A, Bartels U, Chintagumpala M, Hassall TE, Gururangan S, McCowage GB, Heath JA, Cohn RJ, Fisher MJ, Srinivasan A, Robinson GW, Gajjar A.

Int J Radiat Oncol Biol Phys. 2015 Sep 1;93(1):47-53. doi: 10.1016/j.ijrobp.2015.05.019. Epub 2015 May 19.

33.

Cervicomedullary tumors in children.

McAbee JH, Modica J, Thompson CJ, Broniscer A, Orr B, Choudhri AF, Boop FA, Klimo P Jr.

J Neurosurg Pediatr. 2015 Oct;16(4):357-66. doi: 10.3171/2015.5.PEDS14638. Epub 2015 Jun 26.

PMID:
26114990
34.

Corrigendum: Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss.

Xu H, Robinson GW, Huang J, Lim JY, Zhang H, Bass JK, Broniscer A, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Fisher M, Cohn R, Yamashita T, Teitz T, Zuo J, Onar-Thomas A, Gajjar A, Stewart CF, Yang JJ.

Nat Genet. 2015 Apr;47(4):423. doi: 10.1038/ng0415-423. No abstract available.

PMID:
25814313
35.

Delayed diagnosis of childhood low-grade glioma: causes, consequences, and potential solutions.

Arnautovic A, Billups C, Broniscer A, Gajjar A, Boop F, Qaddoumi I.

Childs Nerv Syst. 2015 Jul;31(7):1067-77. doi: 10.1007/s00381-015-2670-1. Epub 2015 Mar 6.

36.

Malignant transformation of low-grade gliomas in children: lessons learned from rare medical events.

Broniscer A.

J Clin Oncol. 2015 Mar 20;33(9):978-9. doi: 10.1200/JCO.2014.60.1823. Epub 2015 Feb 9. No abstract available.

PMID:
25667289
37.

Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss.

Xu H, Robinson GW, Huang J, Lim JY, Zhang H, Bass JK, Broniscer A, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Fisher M, Cohn R, Yamashita T, Teitz T, Zuo J, Onar-Thomas A, Gajjar A, Stewart CF, Yang JJ.

Nat Genet. 2015 Mar;47(3):263-6. doi: 10.1038/ng.3217. Epub 2015 Feb 9. Erratum in: Nat Genet. 2015 Apr;47(4):423.

38.

Pubertal development and primary ovarian insufficiency in female survivors of embryonal brain tumors following risk-adapted craniospinal irradiation and adjuvant chemotherapy.

DeWire M, Green DM, Sklar CA, Merchant TE, Wallace D, Lin T, Vern-Gross T, Kun LE, Krasin MJ, Boyett JM, Wright KD, Wetmore C, Broniscer A, Gajjar A.

Pediatr Blood Cancer. 2015 Feb;62(2):329-334. doi: 10.1002/pbc.25274. Epub 2014 Oct 18.

39.

Incidental diagnosis of diffuse intrinsic pontine glioma in children.

Wright KD, Sabin ND, Cheuk D, McNall-Knapp R, Shurtleff SA, Gajjar A, Broniscer A.

Pediatr Blood Cancer. 2015 Jun;62(6):1081-3. doi: 10.1002/pbc.25408. Epub 2015 Jan 16.

40.

Management of diffuse intrinsic pontine glioma in children: current and future strategies for improving prognosis.

Kaye EC, Baker JN, Broniscer A.

CNS Oncol. 2014 Nov;3(6):421-31. doi: 10.2217/cns.14.47. Review.

41.

Effective treatment of cerebral mucormycosis associated with brain surgery.

Chamdine O, Gaur AH, Broniscer A.

Pediatr Infect Dis J. 2015 May;34(5):542-3. doi: 10.1097/INF.0000000000000626.

42.

Subsequent neoplasms in survivors of childhood central nervous system tumors: risk after modern multimodal therapy.

Tsui K, Gajjar A, Li C, Srivastava D, Broniscer A, Wetmore C, Kun LE, Merchant TE, Ellison DW, Orr BA, Boop FA, Klimo P, Ross J, Robison LL, Armstrong GT.

Neuro Oncol. 2015 Mar;17(3):448-56. doi: 10.1093/neuonc/nou279. Epub 2014 Nov 13.

43.

Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections.

Wright KD, Panetta JC, Onar-Thomas A, Reddick WE, Patay Z, Qaddoumi I, Broniscer A, Robinson G, Boop FA, Klimo P Jr, Ward D, Gajjar A, Stewart CF.

Cancer Chemother Pharmacol. 2015 Jan;75(1):27-35. doi: 10.1007/s00280-014-2614-6. Epub 2014 Oct 24.

44.

Successive distinct high-grade gliomas in L-2-hydroxyglutaric aciduria.

Patay Z, Orr BA, Shulkin BL, Hwang SN, Ying Y, Broniscer A, Boop FA, Ellison DW.

J Inherit Metab Dis. 2015 Mar;38(2):273-7. doi: 10.1007/s10545-014-9782-8. Epub 2014 Oct 23.

45.

Quantitative longitudinal evaluation of diaschisis-related cerebellar perfusion and diffusion parameters in patients with supratentorial hemispheric high-grade gliomas after surgery.

Patay Z, Parra C, Hawk H, George A, Li Y, Scoggins M, Broniscer A, Ogg RJ.

Cerebellum. 2014 Oct;13(5):580-7. doi: 10.1007/s12311-014-0575-2.

PMID:
24917518
46.

Prospective evaluation of local control and late effects of conformal radiation therapy in children, adolescents, and young adults with high-grade glioma.

Vern-Gross TZ, Schreiber JE, Broniscer A, Wu S, Xiong X, Merchant TE.

Neuro Oncol. 2014 Dec;16(12):1652-60. doi: 10.1093/neuonc/nou101. Epub 2014 Jun 7.

47.

Determination of crizotinib in human and mouse plasma by liquid chromatography electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS).

Roberts MS, Turner DC, Broniscer A, Stewart CF.

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jun 1;960:151-7. doi: 10.1016/j.jchromb.2014.04.035. Epub 2014 Apr 28.

48.

Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas.

Qaddoumi I, Kocak M, Pai Panandiker AS, Armstrong GT, Wetmore C, Crawford JR, Lin T, Boyett JM, Kun LE, Boop FA, Merchant TE, Ellison DW, Gajjar A, Broniscer A.

Front Oncol. 2014 Apr 1;4:67. doi: 10.3389/fonc.2014.00067. eCollection 2014.

49.

The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma.

Wu G, Diaz AK, Paugh BS, Rankin SL, Ju B, Li Y, Zhu X, Qu C, Chen X, Zhang J, Easton J, Edmonson M, Ma X, Lu C, Nagahawatte P, Hedlund E, Rusch M, Pounds S, Lin T, Onar-Thomas A, Huether R, Kriwacki R, Parker M, Gupta P, Becksfort J, Wei L, Mulder HL, Boggs K, Vadodaria B, Yergeau D, Russell JC, Ochoa K, Fulton RS, Fulton LL, Jones C, Boop FA, Broniscer A, Wetmore C, Gajjar A, Ding L, Mardis ER, Wilson RK, Taylor MR, Downing JR, Ellison DW, Zhang J, Baker SJ.

Nat Genet. 2014 May;46(5):444-450. doi: 10.1038/ng.2938. Epub 2014 Apr 6.

50.

"Occult" post-contrast signal enhancement in pediatric diffuse intrinsic pontine glioma is the MRI marker of angiogenesis?

Conway AE, Reddick WE, Li Y, Yuan Y, Glass JO, Baker JN, Kun LE, Broniscer A, Patay Z.

Neuroradiology. 2014 May;56(5):405-12. doi: 10.1007/s00234-014-1348-9. Epub 2014 Mar 14.

Supplemental Content

Loading ...
Support Center